Log In or Create Account

CROI
Conference on Bacteriophages
RWHAP Clinical Conference
Podcasts
Slides
Question of the Week
Donate
Contact

Advanced Search

CME Courses
CME Webinars
Dialogues
Topics In Antiviral Medicine
HIV Drug Resistance
Fellow Resources
About

Hyman Scott, MD, MPH

Hyman Scott, MD, MPH

University of California San Francisco

San Francisco, CA

Assistant Clinical Professor, School of Medicine

San Francisco, CA

131 Steuart St, Suite 500, San Francisco, CA 94105

Phone: (415) 544-9400 | info@iasusa.org

Home
Activities
Resources
About
Contact
Login
Careers
Donate
Website Policies

© 2025 International Antiviral Society–USA. All Rights Reserved.

CROI
Conference on Bacteriophages
RWHAP Clinical Conference
Podcasts
Slides
Question of the Week
Donate
Contact
CME Courses
CME Webinars
Dialogues
Topics In Antiviral Medicine
HIV Drug Resistance
Fellow Resources
About

Practice Question of the Week

April 14, 2025: Viral Suppression in the HIV Prevention Trials Network 083 Study

Of the 47 participants in the HIV Prevention Trials Network (HPTN) 083 (Injectable Cabotegravir Compared to TDF/FTC For PrEP in HIV-Uninfected Men and Transgender Women Who Have Sex With Men) who were exposed to long-acting cabotegravir (CAB-LA) who became infected with HIV, what proportion achieved viral suppression on their first antiretroviral regimen?
- A. 52%
- B. 64%
- C. 77%
- D. 93%

Register for the Webinar

View Archived Questions